SBC Medical Group Holdings Incorporated is a medical services organization that provides management support to aesthetic clinics, dermatology practices, dental offices, and other medical institutions. The company offers services including marketing, staff recruitment and training, booking systems, IT solutions, and the procurement of medical equipment and cosmetic products. It operates a network of franchisee clinics in Japan and owns and operates treatment centers in Singapore and Vietnam. The group also pursues U.S. market initiatives through a strategic investment in OrangeTwist and has acquired a controlling interest in Waqoo, a regenerative medicine research company. Key subsidiaries include Aesthetic Healthcare Holdings, MB career lounge, and Shoubikai Medical Vietnam. The company supports medical corporations in Japan, Singapore, Vietnam, and the United States, with a focus on cosmetic surgery, dermatology, and dentistry.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Specialty Business Services Homepage sbc-holdings.com
Sector Industrials IR page ir.sbc-holdings.com
Tags
medical services organization, aesthetic medicine, dermatology, dentistry, regenerative medicine, clinic management, medical marketing, staff recruitment, it solutions, cosmetic products, SBC Medical Group Inc., Aesthetic Healthcare Holdings, MB career lounge, Shoubikai Medical Vietnam, Waqoo, OrangeTwist, L’Ange Cosmetique, SBC Japan, Shonan Beauty Clinic, Medical Corporation Shobikai, Medical Corporation Kowakai, Medical Corporation Nasukai, SBC sealane, Medical Payment, BLEZ ASIA
Press page sbc-holdings.com/news

Metrics

Valuation  
Market cap $ 506.73M
Market cap (USD) $ 506.73M
P/E 9.69
PEG —
P/BV 1.77
P/S 2.66
P/OCF 4.96
P/FCF 5.06
Dividend yield —
Turnover / mcap —
Returns  
ROE 23.0%
ROI 17.5%
ROIC 14.4%
Profit margin 29.4%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 11.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score 62.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024
Revenue 173.607M 205.416M
Net profit 50.986M 46.614M
Free cash flow 23.267M 18.018M

Figure FY 2025 FY 2024
Share price 4.31 5.56
Price performance 12m -0.22 -0.48

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — 1M 262,095 228,210
Lease liabilities (USD) — 6.33M 5.58M 8.8M
Cash and deposits (USD) 485,564 284,394 125M 164M
Intangible assets (USD) — 19.7M 1.59M 47.7M
Right-of-use assets (USD) — 5.92M 5.27M 8.37M
Net debt (borrowings + leases - cash) (USD) — -96.4M -119M -155M
Cash flow detail
Operating cash flow (USD) — -2.13M 20.6M 24.7M
Purchases of property, plant and equipment (USD) — -8.54M -2.56M -1.4M
Purchases of intangible assets (USD) — -1.68M — —
Change in inventories (cash effect) (USD) — -1.83M 1.12M -170,174
Change in payables (cash effect) (USD) — -35,530 — —
Share buybacks (cash effect) (USD) — — 0.00 -5M
Interest paid (cash effect) (USD) — -45,292 -28,300 -160,583
Income taxes paid (cash effect) (USD) — -992,045 -30.2M -37.2M
Share-based compensation (USD) — — 13M 0.00
Free cash flow (OCF - PPE - intangibles) (USD) — 40.4M 18M 23.3M
Income detail
Total comprehensive income (USD) — 25.7M 30.1M 48.1M
Comprehensive income to owners (USD) — 26.6M 30M 47.9M
Provision for credit losses (USD) — 370,754 622,804 0.00
Reported Mar 9, 2023 Mar 28, 2025 Mar 27, 2026 Mar 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement

—(BUSINESS WIRE)—

IRVINE, Calif. -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026).

■ Third Quarter 2026 Financial Highlights

•Total revenues were $59 million, up 35% year-over-year.

•Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%.

•Net income attributable to SBC Medical was $16 million, up 22% year-over-year. Net income margin was 27%, a decrease of 3 percentage points year-over-year.

2026-11-02

Companies to co-develop AI features, starting with physician documentation support, to enhance medicalforce and SBC Medical’s in-house systems and drive per-clinic productivity and profitability

IRVINE, Calif. –SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it entered into a capital and business alliance agreement on October 26, 2026, with AtomicSoftware Inc. (“AtomicSoftware”), the Tokyo-based provider of medicalforce, an all-in-one software-as-a-service (SaaS) platform for clinics. In connection with the alliance, SBC Medical has invested ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round. The two companies will co-develop AI features, beginning with a feature that supports physicians in preparing medical records.

Key Highlights

  • Proven platform: medicalforce is used by more than 800 clinics*1 in Japan, primarily self-pay clinics, with a clinic retention rate of 99.2%*4.
  • Joint AI development: Features co-developed by the two companies will enhance medicalforce and be progressively incorporated into SBC Medical’s own clinic operations systems.
  • Per-clinic economics: By freeing physician and staff time from documentation and administrative work, SBC Medical aims to raise productivity and profitability at each clinic.
  • Scalable growth: Standardized implementation procedures are expected to shorten clinic opening preparations and support faster operational stability as SBC Medical expands its network of 287 clinics*2.
  • Strategic investment: SBC Medical has invested ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round.

Strategic Rationale

SBC Medical’s growth as an MSO has been built on standardizing the systems required for clinic operations and deploying them across the Group. Standardization and digitalization are central to the Company’s business model, enabling it to expand its network while maintaining consistent operational quality. The Company regards investment in the systems and processes behind this model as an important growth investment, including as a means of continuing to raise its repeat rate of 72%*3.

At self-pay clinics, reservations, electronic medical records, payments, and post-visit follow-up run as one continuous daily workflow. For AI to deliver tangible results, it must be embedded in that workflow as features physicians and staff use every day. By combining SBC Medical’s on-the-ground operational experience with AtomicSoftware’s expertise in building the specific requirements of self-pay clinics into its products, the companies aim to reduce the burden of documentation and verification and allow more time to be devoted to customers.

The alliance builds on an existing operating relationship. Hada no Aozora Clinic, a clinic to which SBC Medical provides management support, already uses medicalforce as its core operating and payment system, and the knowledge and track record gained through this real-world use led to the alliance. Through this alliance, the two companies will move beyond a provider-user relationship to become partners that jointly explore and realize better approaches to clinic operations.

Why AtomicSoftware

In just over five years since its launch, medicalforce has been adopted by more than 800 self-pay clinics*1 in Japan, including aesthetic surgery and aesthetic dermatology clinics, and supports reservation management, electronic medical records, payments, customer information management, and business analytics in a single system, with a clinic retention rate of 99.2%*4. Its product strength lies in addressing operational needs specific to self-pay clinics, such as reservations that link rooms, equipment, and staff with treatment menus, and the management of prepaid treatment courses and case photographs. Through its AI feature suite, medicalforce intelligence, AtomicSoftware is also developing capabilities for drafting medical records from voice, summarizing medical record information, and supporting post-visit follow-up. Its ISO/IEC 27001:2022 certification, the international standard for information security management, provides a foundation of trust for handling customer information. SBC Medical believes that drawing on this development and operational expertise, rooted in clinical settings in Japan, will accelerate the practical application of the joint development results and the evolution of its in-house systems.

Scope of the Collaboration

The two companies will co-develop AI-powered features, beginning with a feature that supports physicians in preparing medical records. Features will be validated and refined at clinics to which SBC Medical provides management support to ensure they are practical in clinical settings, then used to enhance medicalforce and progressively incorporated into the Company’s clinic operations systems. By reducing the time physicians and staff spend on documentation and administrative work, the Company aims to increase the time available for each customer, enable more customers to be served with limited staff, and improve productivity and profitability per clinic.

Building on the operational track record at Hada no Aozora Clinic, the companies will also consider how medicalforce can be applied to new clinic brands and business formats according to their operational characteristics. By jointly establishing implementation procedures, they aim to shorten clinic opening preparations and achieve early operational stability, strengthening the operational foundation that supports network expansion.

Comments

Yoshiyuki Aikawa, CEO, SBC Medical Group Holdings Incorporated

“Clinic profitability depends on how much of our physicians’ and staff members’ time can be directed toward customers. AI is an effective way to create that time, but its value is realized only when it is embedded in the systems used every day in clinical settings. AtomicSoftware has gained a deep understanding of our operations through the adoption of medicalforce at Hada no Aozora Clinic. We chose a capital and business alliance because, rather than buying AI off the shelf, we want to co-create it and build it into our own operating capabilities. We believe the resulting productivity gains will raise profitability at our existing clinics, help new clinics get on track quickly, and create a long-term competitive advantage. We are fully committed to enhancing corporate value.”

Shoichi Hatanaka, Representative Director and CEO, AtomicSoftware Inc.

“As AI moves into practical use, the standards required of clinic software are rising every year. Both of our representative directors are engineers by background, and since our founding, our strength has been building the specific operations of clinics offering self-pay and insurance-covered care into our products, continuously improving medicalforce together with clinical teams. Through this alliance, we will expand our development organization and, drawing on expertise accumulated at the forefront of aesthetic healthcare, enhance the value of medicalforce, accelerate its development, and deliver its value to more customers.”

Overview of the Capital and Business Alliance

Partner: AtomicSoftware Inc.

Agreement date: October 26, 2026

Scope of the alliance: Collaboration in the area of clinic operations systems; joint development of AI features and implementation of the results in the Company’s own systems; consideration of system deployment for new clinic brands and business formats

Capital alliance: SBC Medical’s investment of ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round

About AtomicSoftware Inc.

Company name: AtomicSoftware Inc.

Founded: November 2020

Location: Sumitomo Fudosan Nishi-Gotanda Building 4F, 3-6-21 Nishi-Gotanda, Shinagawa-ku, Tokyo, Japan

Representatives: Shoichi Hatanaka, Representative Director and CEO; Ryusuke Kumita, Representative Director and CTO

Business: Development and provision of medicalforce, an all-in-one SaaS for clinics, and Keibi Force, an integrated management system for security companies

Website: https://atomic-software.co.jp/

*1 Number of clinics using medicalforce, as of September 2026 (as announced by AtomicSoftware)

*2 Number of clinics in SBC Medical’s network in Japan and overseas, as of the end of July 2026

*3 Percentage of customers who visited SBC brand, Rize Clinic, or Gorilla Clinic franchise locations two or more times in the fiscal year ended December 31, 2025 (excluding free consultations)

*4 Clinic retention rate of medicalforce, as of March 2026 (based on AtomicSoftware’s data)

Note: The initiatives under this alliance are based on current plans and are subject to change.

Note: U.S. dollar amounts are based on the exchange rate as of October 30, 2026.

About SBC Medical Group Holdings Incorporated

SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, hair loss treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

2026-10-22

Leveraging the Waqoo Group’s research and technology ecosystem to establish a new personal baseline for proactive health and longevity

IRVINE, Calif. –SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it has commenced in-house development of a test designed to estimate an individual’s biological age using DNA methylation analysis.

Development will be led by the Company’s AI and longevity-focused subsidiary, SBC AI Longevity Innovation, Inc. The initiative will leverage the regenerative medicine research and technology base established by Waqoo, Inc. (TSE: 4937), a consolidated subsidiary of SBC Medical, and its subsidiary Cell Pro Japan Co., Ltd. (together, the “Waqoo Group”). The test aims to provide insight into an individual’s physical condition that chronological age alone cannot capture, offering a personal baseline for data-driven wellness and lifestyle adjustments.

The Global Shift: From Lifespan to Healthspan

Modern healthcare is undergoing a paradigm shift from extending lifespan (years lived) to optimizing healthspan (years lived in good health). Global capital and scientific research are rapidly converging on the longevity sector, a key field for SBC Medical’s expansion.

  • Market Growth: The global longevity market is projected to grow from approximately $800 billion in 2025 to approximately $2 trillion by 2035*1.
  • The Longevity Imperative: As one of the world’s oldest populations, Japan is well positioned to lead the development of accessible healthspan solutions.

Bridging Molecular Research with Clinical Expertise

While public interest in proactive wellness continues to grow, objective and repeatable ways to track the body’s internal condition over time remain limited. SBC Medical aims to address this gap by bridging science with seasoned clinical execution.

  • Scientific Base: Integrating the cellular and molecular research competencies built by the Waqoo Group through its regenerative medicine operations.
  • Clinical Scale: Leveraging SBC Medical’s extensive clinic operations infrastructure and customer experience know-how derived from its core MSO operations.

Why DNA Methylation?

Unlike an individual’s genetic code, epigenetic markers such as DNA methylation can change with environment, diet, stress, and lifestyle. This makes DNA methylation a promising marker to track over time, helping individuals see the real-world impact of lifestyle changes.

Scientific understanding of epigenetic clocks has advanced since the first landmark methodology was published in 2013*2. Notably, in 2025, researchers demonstrated a method to estimate the ages of 11 distinct organs and physiological systems from a single blood draw*3.

Strategic Development Focus

Building on these research advances, SBC Medical’s development roadmap centers on three core pillars:

  1. Organ-Specific Mapping: Assessing biological age by organ system to identify where in the body aging-related changes are progressing.

  2. Non-Invasive Modalities: Researching highly accessible, consumer-friendly measurement methods that do not require blood draws.

  3. Japan-Specific Data: Building a robust evaluation framework based on data from Japanese cohorts.

A New Standard for Personal Health

Rather than delivering a static, isolated metric, the test is designed to serve as a dynamic “personal baseline.” By enabling individuals to measure their biological age before and after implementing lifestyle changes, SBC Medical aims to establish a continuous feedback loop that visualizes changes in the body, supporting long-term health literacy and engagement.

*1 Report Ocean, “Global, US & Japan Longevity Market” (published March 2026)

*2 Horvath S. DNA methylation age of human tissues and cell types. Genome Biology. 2013;14:R115.

*3 Sehgal R, et al. Systems Age: a single blood methylation test to quantify aging heterogeneity across 11 physiological systems. Nature Aging. 2025;5:1880–1896.

Note: The information in this release is based on current plans and is subject to change.

About SBC AI Longevity Innovation, Inc.

Location: Shinjuku Island Tower 12F, 6-5-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan

Representative Director and President: Yuya Yoshida

Business: Planning and development of products and services in the AI and longevity fields; provision of AI solutions and operational support for medical institutions

Website: https://sbc-ai-longevity.com/

About Waqoo, Inc.

Location: 2-14-1 Kamiuma, Setagaya-ku, Tokyo, Japan

Representative Director and President: Bumpei Samata

Listing: Tokyo Stock Exchange Growth Market (Securities Code: 4937)

Business: Medical support business; D2C and subscription business

Website: https://waqoo.jp/

About Cell Pro Japan Co., Ltd.

Location: Shonan iPark, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan

Representative Director and President: Bumpei Samata

Business: Regenerative medicine-related business

Website: https://cellprojapan.com/

About SBC Medical Group Holdings Incorporated

SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, hair loss treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

Prompts

SBC Medical Group Holdings Incorporated (ticker SBC), listed in United States.

Company History

Date Change Detail
Sep 17, 2024 Renamed PONO CAPITAL TWO, INC. → SBC MEDICAL GROUP HOLDINGS INC
— Former tickers PTWO

ETFs Holding SBC Medical Group Holdings Incorporated

ETF Weight in ETF Shares Market value As of
AVUV 0.01% 269,502 $ 1.666M Nov 16, 2026
AVSC 0.00% 25,689 $ 158.758K Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
SBC canonical Common share — US nasdaq 4.94 USD 2026-09-30
SBCWW Warrant — US nasdaq 0.35 USD 2026-09-30